Oregon Public Employees Retirement Fund boosted its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 1.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 377,319 shares of the biopharmaceutical company’s stock after buying an additional 4,800 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Bristol-Myers Squibb were worth $21,024,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Guardian Capital Advisors LP purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $554,000. Zurich Insurance Group Ltd FI raised its stake in Bristol-Myers Squibb by 43.0% in the fourth quarter. Zurich Insurance Group Ltd FI now owns 325,956 shares of the biopharmaceutical company’s stock valued at $19,049,000 after buying an additional 97,990 shares during the period. Tyers Asset Management LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at $818,000. Graham Capital Management L.P. acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at $982,000. Finally, Menta Capital LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at $1,905,000. 69.79% of the stock is owned by institutional investors.
Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.25% during mid-day trading on Friday, reaching $56.73. 4,060,530 shares of the company’s stock traded hands. The firm has a 50 day moving average of $55.80 and a 200 day moving average of $54.64. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $60.86. The firm has a market cap of $93.03 billion, a PE ratio of 20.72 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the previous year, the company posted $0.69 earnings per share. The business’s revenue was up 5.6% on a year-over-year basis. Analysts forecast that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were paid a $0.39 dividend. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 annualized dividend and a yield of 2.75%. Bristol-Myers Squibb’s payout ratio is 56.73%.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Bought by Oregon Public Employees Retirement Fund” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/08/12/oregon-public-employees-retirement-fund-has-21-02-million-stake-in-bristol-myers-squibb-company-bmy-updated-updated-updated.html.
Several research analysts have commented on the stock. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price for the company in a research report on Wednesday, July 12th. BMO Capital Markets restated a “market perform” rating and issued a $45.00 target price on shares of Bristol-Myers Squibb in a research report on Sunday, April 23rd. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Leerink Swann decreased their price objective on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $62.12.
In other news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is owned by corporate insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.